Pfizer reports positive results from Phase IIb trial of berobenatide
Pfizer has reported detailed Phase IIb results for its investigational monthly glucagon-like peptide-1 receptor agonist (GLP-1 RA) peptide, berobenatide (PF’3944),…
All articles by Salong Debbarma
Salong Debbarma
-
-
Novo Nordisk reports Phase II data for zenagamtide in diabetes
Novo Nordisk has reported results from its Phase II study of zenagamtide, an investigational once-weekly subcutaneous treatment, showing statistically significant…
-
Novartis reports positive results from Phase III ALIGN trial for IgAN
Novartis has announced final results from the Phase III ALIGN study, highlighting that Vanrafia (atrasentan) slows kidney function decline versus…
-
First patient dosed in Onchilles’ Phase I/II trial of N17350
Onchilles Pharma has dosed the first patient in its Phase I/II clinical trial of N17350, the lead tumour-directed therapeutic candidate,…
-
Massive Bio and Optellum partner on early NSCLC detection and trials
Massive Bio and Optellum have formed a partnership to integrate early detection of non-small cell lung cancer (NSCLC) with access…
-
J&J’s nipocalimab meets primary endpoint in Phase II JASMINE study
Johnson & Johnson (J&J) has reported that its monoclonal antibody, nipocalimab, met the primary endpoint in the Phase II JASMINE…
-
Inipharm commences dosing in INI-822 trial for MASH
Inipharm has started dosing in a 12-week proof-of-concept clinical study evaluating its oral hydroxysteroid 17-beta-dehydrogenase 13 (HSD17B13) inhibitor, INI-822, in…
-
Moonlight begins SURVEYOR Phase I trial for peanut allergy
Moonlight Therapeutics has begun the SURVEYOR Phase I clinical trial to assess MOON101, an investigational immunotherapy for peanut allergy. The…
-
Abivax’s obefazimod met primary endpoint in Phase III ABTECT trial
Abivax has reported that the Phase III ABTECT maintenance trial of obefazimod, its investigational oral, first-in-class miR-124 enhancer, met the…
-
Jade reports interim Phase I results of JADE101 for IgAN
Jade Biosciences has reported positive interim data from its Phase I trial studying JADE101, an investigational anti-A proliferation-inducing ligand (APRIL)…